HOLON, ISRAEL, March 8,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that management will participate in a fireside
chat at the Oppenheimer 33rd Annual Healthcare Conference
(virtual), on Wednesday, March 15,
2023 at 10:00 AM ET.
A live webcast of the fireside chat will be available on the
Investor Relations section of Compugen's website at
www.cgen.com. A replay will be available following the live
event for 90 days.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, that is in
Phase 2 development by AstraZeneca through a license agreement for
the development of bi-specific and multi-specific
antibodies. In addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is advancing in IND enabling
studies. COM503 is a potential first-in-class, high affinity
antibody which blocks the interaction between IL-18 binding protein
and IL-18, thereby releasing the natural IL-18 into the tumor
microenvironment to inhibit cancer growth. Compugen is
headquartered in Israel, with
offices in San Francisco,
CA. Compugen's shares are listed on Nasdaq and the Tel
Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-a-fireside-chat-at-the-oppenheimer-33rd-annual-healthcare-conference-301765512.html
SOURCE Compugen Ltd.